Vaccins contre le papillomavirus humain et prévention des cancers gynécologiques: Résultats actuels et nouvelles perspectives [HPV vaccines and prevention of gynecological cancers: Current results, new perspectives]

Abstract

National audienceThe HPV vaccine is the result of progress in the knowledge of HPV-induced malignancies and represents an hope for primary prevention of many epithelial cancers, mainly the cervix cancer in women. Its efficacy and safety are proven by methodologically adequate trials (randomized double-blind trials). The impact of the vaccine on large populations begins to be perceived in countries with proactive vaccination programs. Unfortunatly, vaccination brakes exist today in France explaining the relative failure of vaccination: the conviction of doctors, and the establishment of an early and wide vaccination program under the authority of government could overcome this reluctance. Progresses can be expected with the development of vaccine containing new genotypes, as in the nonavalent vaccine that compares favorably with the quadrivalent vaccine. Copyright © 2016 JLE